Categories
Change Password!
Reset Password!
The use of bimekizumab can
mitigate the symptoms of plaque psoriasis.
Based on the outcomes of a 56-week study published in ‘The New England Journal of Medicine’, bimekizumab was found to be superior to adalimumab in terms of providing symptom relief of plaque psoriasis over a period of 16 weeks. Nevertheless, its use was also associated with increased episodes of oral candidiasis and diarrhea. Richard B. Warren and colleagues examined the safety and efficacy of bimekizumab (monoclonal IgG1 antibody) with adalimumab (tumor necrosis factor inhibitor) for plaque psoriasis.
On the whole, 478
patients (mean aged 44.9 years) with moderate-to-severe plaque psoriasis were
recruited and randomized into groups of three to receive:
Initially, the mean Psoriasis Area and Severity Index (PASI score) were 19.8. At week 16, PASI 90 response was observed in 86.2% of patients who received bimekizumab and 47.2% with adalimumab. The Investigator’s Global Assessment (IGA) score of 0 (clear skin) or 1 was observed in 85.3% patients receiving bimekizumab and 57.2% patients receiving adalimumab as described in the following table:
Upper respiratory tract infections, oral candidiasis (mostly
mild or moderate), diarrhea, and hypertension were the most frequent adverse
events linked with bimekizumab use. Future long-term studies concerning bimekizumab’s effectiveness
in plaque psoriasis treatment with other agents are needed, study authors
mentioned.
The New England Journal of Medicine
Bimekizumab versus Adalimumab in Plaque Psoriasis
Richard B. Warren et al.
Comments (0)